The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View pso content recommended for you
AAD 2024: Highlights from the IPC report
The American Academy of Dermatology (AAD) Annual Meeting 2024 was held in San Diego, U.S., from March 8–12.1 AAD is one of the largest dermatology conferences in the world, with over 1,000 speakers and 300 sessions.1
The International Psoriasis Council (IPC) has provided a report that includes summaries of all 36 talks on psoriasis topics at AAD, and the IPC symposium, which focused on the comprehensive care of psoriasis.1 The IPC is a community of researchers and physicians who work to improve the lives of individuals living with psoriasis.1 Here, we provide a short summary of information included in the report.
Coverage of psoriatic disease1
Key topics covered at AAD included:
-
Biomarkers in psoriasis
-
Evolving treatment landscapes and pipeline therapies
-
Management of nail psoriasis
-
Interleukin inhibitors for psoriasis and psoriatic arthritis
-
Biosimilars
-
Impact of comorbidities in treatment selection
-
Early treatment
-
Psoriasis management in women
Late breaking abstracts1
Topics in the late-breaking abstracts included:
-
52-week results from the phase II KNOCKOUT trial (risankizumab)
-
Light treatment effectiveness (LITE) study
-
Phase II STRIDE study (ESK-001)
-
Phase IIb FRONTIER 2 study (JNJ-77242113)
-
16-week results from a phase III palmoplantar pustulosis trial (apremilast)
-
4-year pooled analysis from BE BRIGHT (bimekizumab)
-
Reducing CD8+ memory T cells in generalized pustular psoriasis (guselkumab)
For a comprehensive understanding of the sessions, the complete report can be found on the IPC website.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content